Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Bausch Health Companies Announces APMA Grants Seal Of Approval For JUBLIA Topical Solution, 10%


Benzinga | Dec 6, 2021 07:02AM EST

Bausch Health Companies Announces APMA Grants Seal Of Approval For JUBLIA Topical Solution, 10%

Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA(r) (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

"We are pleased to receive this distinguished honor by the APMA, the leading professional organization for the more than 12,500 podiatrists in the United States," said Joseph C. Papa, chairman and CEO, Bausch Health. "The APMA Seal of Approval recognizes the demonstrated safety and efficacy profile of JUBLIA(r) and its continued use as a valuable treatment option for adults and children with toenail fungal infections. Since its initial approval to treat adults in 2014 and subsequent approval to treat pediatric patients six years of age and older in 2020, JUBLIA(r) has been available to help podiatrists and patients struggling with onychomycosis."

To earn the APMA Seal of Approval, products must undergo a rigorous scientific review by a committee of APMA podiatrists. The comprehensive review includes objective data from clinical and laboratory studies, patents and quality control, as well as details of intended use and product composition. Following a detailed review of the product by each committee member, a recommendation is sent to the APMA Board of Trustees, which either accepts or rejects the recommendation.

"Toenail fungus is extremely common, but it is an infection--and a highly contagious infection," said Jeffrey R. DeSantis, DPM, FACFAS, president of the American Podiatric Medical Association. "APMA is proud to bestow its Seal of Approval on products such as JUBLIA(r) that meet our physicians' highest standards for safety and effectiveness."

For more information on JUBLIA(r), visit http://www.jubliarx.com/.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC